Market Cap 924.04M
Revenue (ttm) 0.00
Net Income (ttm) -68.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 660,600
Avg Vol 555,548
Day's Range N/A - N/A
Shares Out 54.61M
Stochastic %K 57%
Beta N/A
Analysts Strong Sell
Price Target $32.14

Company Profile

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 617 468 4219
Address:
116 Huntington Avenue, Suite 703, Boston, United States
_www_larval_com_
_www_larval_com_ Oct. 20 at 6:08 PM
$BCAX has reverted 3% higher to -13% (~2Mv) moments ago, 11/21 options, follow for more volatility.
0 · Reply
Arcides
Arcides Oct. 20 at 2:37 PM
$BCAX a little haircut on resistance zone....
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 16 at 4:23 PM
$AMKR $BCAX $APPS $ASPN Cycle Trading Signal plugged into AI 🔥
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 16 at 1:26 PM
$BCAX another one OCT 25 list! This 2 list covers 2 deferent time frame using same process the one that don't qualify under 1 time frame will qualify under the other that way they both work so good together under 2 deferent time frames. Cycle Trading Signal plugged into AI 🔥 lists OCT 25 and 10/10/25
0 · Reply
topstockalerts
topstockalerts Oct. 13 at 2:09 PM
Shares of Bicara Therapeutics Inc. rose in premarket trading Monday after the company said its cancer therapy ficerafusp alfa received Breakthrough Therapy Designation (BTD) from the FDA. The BTD covers ficerafusp alfa combined with pembrolizumab as a first-line treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma expressing PD-L1, excluding HPV-positive cases. The decision was based on Phase 1/1b data showing a median response duration of 21.7 months and overall survival of 21.3 months, with a favorable safety profile, presented at the 2025 ASCO Annual Meeting. CEO Claire Mazumdar said the designation validates ficerafusp alfa’s best-in-class potential and supports the ongoing FORTIFI-HN01 pivotal trial. The FDA’s BTD aims to accelerate development and review of drugs showing substantial improvement over existing therapies. $BCAX
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 13 at 12:39 PM
$BCAX (+6.3% pre) Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC https://ooc.bz/l/80242
0 · Reply
SlicingOnions
SlicingOnions Oct. 13 at 12:37 PM
$BCAX BTD is now a sell the news event?
1 · Reply
stocktuit
stocktuit Oct. 13 at 12:02 PM
$BCAX it sold off like crazy after the BTD news
0 · Reply
notreload_ai
notreload_ai Oct. 13 at 11:59 AM
$BCAX ficerafusp alfa receives FDA Breakthrough Therapy Designation for HPV-negative head and neck cancer, showing impressive response rates and survival benefits. https://notreload.xyz/fda-grants-breakthrough-status-promising-head-neck-cancer-treatment/
0 · Reply
MahiMe
MahiMe Oct. 13 at 11:39 AM
$BCAX $BCAX Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC https://www.stocktitan.net/news/BCAX/bicara-therapeutics-announces-ficerafusp-alfa-granted-breakthrough-ku6cy84xketa.html
0 · Reply
Latest News on BCAX
Bicara: Innovative Precision Tumor Targeting

Apr 19, 2025, 6:22 AM EDT - 6 months ago

Bicara: Innovative Precision Tumor Targeting


_www_larval_com_
_www_larval_com_ Oct. 20 at 6:08 PM
$BCAX has reverted 3% higher to -13% (~2Mv) moments ago, 11/21 options, follow for more volatility.
0 · Reply
Arcides
Arcides Oct. 20 at 2:37 PM
$BCAX a little haircut on resistance zone....
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 16 at 4:23 PM
$AMKR $BCAX $APPS $ASPN Cycle Trading Signal plugged into AI 🔥
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 16 at 1:26 PM
$BCAX another one OCT 25 list! This 2 list covers 2 deferent time frame using same process the one that don't qualify under 1 time frame will qualify under the other that way they both work so good together under 2 deferent time frames. Cycle Trading Signal plugged into AI 🔥 lists OCT 25 and 10/10/25
0 · Reply
topstockalerts
topstockalerts Oct. 13 at 2:09 PM
Shares of Bicara Therapeutics Inc. rose in premarket trading Monday after the company said its cancer therapy ficerafusp alfa received Breakthrough Therapy Designation (BTD) from the FDA. The BTD covers ficerafusp alfa combined with pembrolizumab as a first-line treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma expressing PD-L1, excluding HPV-positive cases. The decision was based on Phase 1/1b data showing a median response duration of 21.7 months and overall survival of 21.3 months, with a favorable safety profile, presented at the 2025 ASCO Annual Meeting. CEO Claire Mazumdar said the designation validates ficerafusp alfa’s best-in-class potential and supports the ongoing FORTIFI-HN01 pivotal trial. The FDA’s BTD aims to accelerate development and review of drugs showing substantial improvement over existing therapies. $BCAX
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 13 at 12:39 PM
$BCAX (+6.3% pre) Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC https://ooc.bz/l/80242
0 · Reply
SlicingOnions
SlicingOnions Oct. 13 at 12:37 PM
$BCAX BTD is now a sell the news event?
1 · Reply
stocktuit
stocktuit Oct. 13 at 12:02 PM
$BCAX it sold off like crazy after the BTD news
0 · Reply
notreload_ai
notreload_ai Oct. 13 at 11:59 AM
$BCAX ficerafusp alfa receives FDA Breakthrough Therapy Designation for HPV-negative head and neck cancer, showing impressive response rates and survival benefits. https://notreload.xyz/fda-grants-breakthrough-status-promising-head-neck-cancer-treatment/
0 · Reply
MahiMe
MahiMe Oct. 13 at 11:39 AM
$BCAX $BCAX Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC https://www.stocktitan.net/news/BCAX/bicara-therapeutics-announces-ficerafusp-alfa-granted-breakthrough-ku6cy84xketa.html
0 · Reply
DylanGFM
DylanGFM Oct. 13 at 11:33 AM
$ELBM $PMAX $ACON $STI do y'all see what $BCAX just did
1 · Reply
DonCorleone77
DonCorleone77 Oct. 3 at 9:02 PM
$BCAX Bicara Therapeutics files $400M mixed securities shelf
1 · Reply
StockScanners
StockScanners Oct. 2 at 12:44 AM
$BCAX reached 17.38, lets go team
0 · Reply
StockScanners
StockScanners Oct. 1 at 2:15 AM
$BCAX reached 15.83
0 · Reply
StockScanners
StockScanners Sep. 30 at 1:09 AM
$BCAX keep watch if this holds above 12.80
0 · Reply
100Bandz
100Bandz Sep. 29 at 2:57 PM
$BCAX Trending...
0 · Reply
redistributeW
redistributeW Sep. 29 at 12:00 PM
$BCAX Why is Stocktwits deleting posts and not providing quotes for this company?
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Sep. 23 at 4:26 PM
https://youtube.com/shorts/IpgLeyabf3g?si=8LyClszQXHbp2Uns $BCAX $BCBP $BCH
0 · Reply
GhostTrend
GhostTrend Aug. 23 at 7:05 AM
$BCAX BCA Acquisition Corp is another SPAC with time limitation to find target
1 · Reply
JarvisFlow
JarvisFlow Aug. 19 at 12:00 PM
Piper Sandler has adjusted their stance on Bicara Therapeutics ( $BCAX ), setting the rating to Overweight with a target price of 36.
0 · Reply
Pratik2024
Pratik2024 Jun. 26 at 6:02 PM
$BCAX $CURV $DECK $HNRG $IMMX CURV - PR AF or tomorrow.
0 · Reply
Pratik2024
Pratik2024 Jun. 26 at 3:47 PM
$BCAX $CURV $DECK $HNRG $IMMX CURV (when flying is eminent, better buckle up): 1. The secondary public offering is expected to be closed today, 26 June. 2. The company is buying back shares of $20 million.
0 · Reply